Safety, Efficacy and Pharmacokinetics of CBT-006 in Patients With Meibomian Gland Dysfunction

A Phase 2 Multicenter, Double-masked, Randomized, Vehicle-controlled, Parallel Study to Evaluate the Safety, Efficacy and Pharmacokinetics of CBT-006 in Patients With Meibomian Gland Dysfunction

STUDY DESIGN

Structure:

Multicenter, randomized, double-masked, vehicle-controlled, parallel group study.

Duration:

3 months of TID treatment.

Treatment Groups, Dosing, and Treatment Regimen:

Study Treatment: CBT-006 topical ophthalmic solution Control Treatment: CBT-006 vehicle

Study Overview

• Status: Completed
• Conditions: Meibomian Gland Dysfunction
• Intervention / Treatment: Drug: CBT-006

Detailed Description

Structure:

Multicenter, randomized, double-masked, vehicle-controlled, parallel group study.

Duration:

3 months of TID treatment.

Treatment Groups, Dosing, and Treatment Regimen:

Study Treatment: CBT-006 topical ophthalmic solution Control Treatment: CBT-006 vehicle

• Study Type: Interventional
• Enrollment (Actual): 92
• Phase: Phase 2

Contacts and Locations

Study Locations

• United States
  • California
    • Newport Beach, California, United States, 92663
      • Eye Research Foundation

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Diagnosed with MGD in both eyes and meet the following:

  1. Ocular discomfort Score (ODS) ≥ 2
  2. Visual Analog Scale (VAS) level is 35-90% for at least 1 of the 7 categories
  3. Total Cornea staining grade ≥ 3
  4. Total meibum quality score (MQS) is between 6-17 from the sum of the 6 lower eyelid central glands in at least one lower eyelid
  5. TBUT ≤ 5 s
  6. Schirmer I Test (anaesthetized) ≥ 5 mm/5 min in study eye
  7. BCVA LogMAR ≥ +0.7 in each eye
• All patients of both genders ≥ 18 years
• Willing to withhold the use of artificial tears and lubricants during the treatment phase;
• Able to provide written informed consent and comply with study assessments for the full duration of the study.

Exclusion Criteria:

• Uncontrolled systemic disease in the opinion of the Investigator
• Active allergies with symptoms that may confound the data, active ocular infection requiring treatment, or ocular surface inflammatory disease unrelated to MGD or DED, including chalazion, inflamed pinguecula, and viral illness
• History of ocular herpes disease in either eye
• Incisional ocular surgery within 6 months or ocular laser surgery within 3 months
• Use of topical treatment of the eye/eyelid with antibiotics, NSAIDS, or vasoconstrictors to treat MGD or DED within 14 days of screening; steroids, cyclosporin A or lifitegrast within 28 days of screening
• Current or anticipated use of other topical ophthalmic medications in the study eye. (Patients must have discontinued the use of ophthalmic medications in the study eye for at least 2 weeks prior to the screening visit, the use of diagnostic medications as part of the eye exam prior to screening and artificial tears is allowed.)
• Anticipated wearing of contact lenses during any portion of the study. (Patients, who wear soft contact lenses should discontinue wearing them at least 3 days prior to screening visit. Patients wearing rigid gas permeable or hard contact lenses should discontinue wearing them at least 3 weeks prior to screening visit.)
• Active rosacea involving the eyelids within 60 days of screening
• Current enrollment in an investigational drug or device study or participation in such a study within 30 days prior to entry into this study
• Any condition or situation which, in the investigator's opinion, may put the patient at significant risk, may confound the study results, or may interfere significantly with the patient's participation in the study
• Female patients who are pregnant, nursing, or planning a pregnancy during the study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Triple

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Placebo Comparator: CBT-006; Vehicle	Drug: CBT-006; ophthalmic solution; Other Names: not apply
Experimental: CBT-006 lower concentration; lower concentration dose	Drug: CBT-006; ophthalmic solution; Other Names: not apply
Experimental: CBT-006 higher concentration; higher concentration dose	Drug: CBT-006; ophthalmic solution; Other Names: not apply

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
IOP of Study Eye Related to Safety	Intraocular Pressure of study eye related to safety	12 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Ocular discomfort score (0-4)	Change of the ocular discomfort score from baseline (Day 1) at Week 12; Score 0 is the most comfortable and 4 is the least comfortable	3 months

Collaborators and Investigators

• Sponsor: Cloudbreak Therapeutics, LLC
• Investigators: Study Director: Rong Yang, Cloudbreak Therapeutics, LLC

Study record dates

Study Major Dates

• Study Start (Actual): September 5, 2021
• Primary Completion (Actual): August 17, 2023
• Study Completion (Actual): August 17, 2023

Study Registration Dates

• First Submitted: May 5, 2021
• First Submitted That Met QC Criteria: May 7, 2021
• First Posted (Actual): May 12, 2021

Study Record Updates

• Last Update Posted (Actual): April 24, 2024
• Last Update Submitted That Met QC Criteria: April 1, 2024
• Last Verified: August 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Eye Diseases; Eyelid Diseases; Meibomian Gland Dysfunction
• Other Study ID Numbers: CBT-CS102

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No